Clinical trial
EXTEND (Eltrombopag Extended Dosing Study)
NCT00351468 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00351468 |
|---|---|
| Title | EXTEND (Eltrombopag Extended Dosing Study) |
| Official title | EXTEND (Eltrombopag Extended Dosing Study): An Extension Study of Eltrombopag Olamine (SB-497115-GR) in Adults, With Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study. |
| Acronym | EXTEND |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Purpura, Thrombocytopaenic, Idiopathic |
| Intervention type | Drug |
| Interventions | eltrombopag olamine (SB-497115-GR) |
| Enrollment | 302 |
| Start date | Jun 1, 2006 |
| Primary completion | Jul 1, 2015 |
| Completion | Jul 1, 2015 |
| First posted | Jul 12, 2006 |
| Last update posted | Apr 17, 2017 |
| Countries | Australia, Austria, Canada, China, Czechia, Denmark, Finland, France, Germany, Greece, Hong Kong, Italy and 19 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: